NLRP3 and diabetic kidney disease: For example, gene therapy involving IL-22 plays a large role in inhibiting the activation of the NLRP3 inflammasome during podocyte pyroptosis, thereby reducing renal fibrosis and DKD progression (Wang et al. 2017).